BRIEF published on 04/15/2026 at 09:49, 7 days 2 hours ago GBC Kapital Supports Marinomed's Capital Increase Success Biotechnology Capital Increase Marinomed Biotech Financial Flexibility GBC Kapital
BRIEF published on 04/15/2026 at 09:49, 7 days 2 hours ago GBC Kapital soutient le succès de l'augmentation de capital de Marinomed Biotechnologie Augmentation De Capital Flexibilité Financière Biotechnologie Marinomed GBC Capital
PRESS RELEASE published on 04/15/2026 at 09:44, 7 days 2 hours ago GBC Kapital supports successful capital increase of Marinomed Marinomed Biotech AG successfully completes capital increase with support from GBC Kapital GmbH, strengthening financial base and positioning for strategic development Financing Capital Increase Biotechnology Company Marinomed Biotech AG GBC Kapital GmbH
Published on 04/22/2026 at 01:55, 10 hours 24 minutes ago Immutable Holdings Announces Director Resignation
Published on 04/22/2026 at 01:30, 10 hours 49 minutes ago Challenger West Assays Return Grades up to 60g/t Au
Published on 04/22/2026 at 00:00, 12 hours 19 minutes ago Zimtu Capital Corp. and Global Energy Metals Corporation Agree to Terminate Option Agreement for the Monument Peak Copper-Silver Project, Idaho
Published on 04/22/2026 at 00:00, 12 hours 19 minutes ago Grande Portage Resources Announces SEDAR+ Filing of Preliminary Economic Assessment (PEA) Study for the New Amalga Gold Project in SE Alaska
Published on 04/22/2026 at 12:00, 19 minutes ago Ethisphere Names Linde to 2026 World's Most Ethical Companies® List
Published on 04/22/2026 at 11:36, 42 minutes ago Original-Research: Cabka NV (von First Berlin Equity Research GmbH): Kaufen
Published on 04/22/2026 at 11:35, 44 minutes ago Zendure Debuts SolarFlow Mix Series Across Europe -- Three Home Storage Systems, One Platform, Up to 91% Off the Bill
Published on 04/22/2026 at 11:30, 49 minutes ago Notification on the increase of the share capital of Eleving Group
Published on 04/22/2026 at 10:32, 1 hour 47 minutes ago EQS-Adhoc: K+S Aktiengesellschaft: EBITDA and adjusted free cash flow in the first quarter of 2026 significantly above market expectations; EBITDA forecast for the full year 2026 raised
Published on 04/22/2026 at 07:00, 5 hours 19 minutes ago Chiffre d'affaires 1er trimestre 2026. 229,5M€ à devises constantes. 215,5 M€ à devises courantes.
Published on 04/22/2026 at 07:00, 5 hours 19 minutes ago Q1 2026 sales. €229.5m at constant exchange rates. €215.5m at current exchanges rates
Published on 04/21/2026 at 19:15, 17 hours 4 minutes ago AXA - Description of the Company’s share repurchase program
